MORPHOLOGIC EVALUATION OF THE EFFECT OF DENOSUMAB ON GIANT CELL TUMORS OF BONE AND A NEW GRADING SCHEME

Creative Commons License

ERDOĞAN K. E., DEVECİ M. A., PAYDAŞ S., GÖNLÜŞEN G.

POLISH JOURNAL OF PATHOLOGY, cilt.67, sa.4, ss.392-397, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 67 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5114/pjp.2016.65873
  • Dergi Adı: POLISH JOURNAL OF PATHOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.392-397
  • Çukurova Üniversitesi Adresli: Evet

Özet

Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. Recent studies suggest new approaches in light of the elucidation of molecular pathways in bone. The osteolytic nature of GCT is caused by the receptor for activating nuclear factor-kB ligand (RANKL) associated osteoclasts. Denosumab is a monoclonal antibody that affects GCT through RANKL and it prevents normal and neoplastic osteolysis. The aim of this study is to evaluate the histopathologic alterations due to denosumab treatment and the efficiency of this drug in GCT therapy.